Company intelligence / Profile preview

DreamTec Research

Hong Kong, Hong Kong

Ownership: Private
Development stage: Other

Overview

DreamTec Research has developed and commercialized a proprietary platform for large-scale, efficient production of various recombinant proteins and stem cell therapies. Their products include regenerative health-focused cosmetic and oral care products, and functional edible probiotics containing bioactive compounds. The scientific team has published papers and secured patents in the field.

Therapeutic areas: GastroenterologyOtherDermatology
Modalities: Recombinant proteinStem cell therapyExosome-based therapyEdible probiotics3D bio-printing
Industry: Biotech

Partnerships

Academic collaboration with University of Ulsterintention to collaborate with scholars in mainland China for industrial research

Beyond the preview

Go deeper on DreamTec Research.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DreamTec Research.

Explore the full profile